Post

CiMaas will restart

This week CiMaas reached an agreement with several parties for a restart. We are happy to announce that we are able to continue activities on our cell products. Further details will be communicated soon.

Post

CiMaas and CYTEA BIO are pleased to announce their collaboration on Natural Killer cells

Under the agreement, CiMaas will provide CYTEA BIO with the GMP-grade K562-F012 feeder cells for the expansion of its umbilical cord blood-derived NK cells. Conversely, CYTEA BIO will supply CiMaas with Pin™ antibodies for the pre-arming of CiMaas NK cells to assess the benefit it brings and the opportunity to pursue a longer-term partnership.